---
title: "OSE Immunotherapeutics is focusing on advancing late stage value drivers Lusvertikimab and Tedopi with strategic refocusing."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277501599.md"
description: "OSE Immunotherapeutics is strategically refocusing on advancing its late-stage value drivers, Lusvertikimab and Tedopi®. This decision highlights the company's commitment to maximizing these key assets, which are in advanced development stages and crucial for enhancing shareholder value. The realignment aims to streamline focus and allocate resources efficiently, positioning Lusvertikimab and Tedopi® as significant growth opportunities within OSE Immunotherapeutics' portfolio."
datetime: "2026-03-02T17:01:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277501599.md)
  - [en](https://longbridge.com/en/news/277501599.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277501599.md)
generator: "portal-rs"
---

# OSE Immunotherapeutics is focusing on advancing late stage value drivers Lusvertikimab and Tedopi with strategic refocusing.

OSE Immunotherapeutics is ramping up its strategic realignment to progress its late-stage value drivers, Lusvertikimab and Tedopi®. These key assets are currently at advanced stages of development and hold significant promise for the company. The decision to prioritize these programs underscores OSE Immunotherapeutics' commitment to maximizing their potential and enhancing shareholder value. This move comes as part of the company's overarching efforts to streamline its focus and allocate resources efficiently. Lusvertikimab and Tedopi® represent important pillars in OSE Immunotherapeutics' portfolio, with substantial opportunities for growth and success.

### Related Stocks

- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IPA.US](https://longbridge.com/en/quote/IPA.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LYEL.US](https://longbridge.com/en/quote/LYEL.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [MLTX.US](https://longbridge.com/en/quote/MLTX.US.md)

## Related News & Research

- [“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z](https://longbridge.com/en/news/297407072.md)
- [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md)
- [Koala trial doses first patient with novel KMA‑targeting CAR‑T](https://longbridge.com/en/news/298021066.md)
- [EverGen Infrastructure Reports Q2 2026 Results | EVGIF Stock News](https://longbridge.com/en/news/297122882.md)
- [Biotech Stocks Facing FDA Decision In September 2026](https://longbridge.com/en/news/297065559.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**